oral glucose-based formulation

临床试验

计划入组 60 人 · 首次发布于 2025 年 9 月 4 日

已完成

NCT03819491

Bioavailability Study of COQUN ORAL FORMULATION

计划入组 24 人 · 首次发布于 2019 年 1 月 28 日

已完成

NCT06845566

Formulation of Compensation Based Intervention

计划入组 30 人 · 首次发布于 2025 年 2 月 25 日

药物

查看全部 2234 →

nitric oxide-based antiviral formulation

Small Molecule

Approved

Glucose(Bss Ophthalmic Solution, Citrasate, Clinimix 2.75/5, Clinimix E 2.75/5, Dextroject, Dianeal, H.E.L.P.bicel, Hemosate Ultra, Lactate 1-2-3, Leukotrap, Naturalyte, Nauzene, Normosol-R, Nxstage Pureflow, Olimel, Periolimel, Physioneal 40, Sag-M, Sclerodex, Selectbag One)

相关疾病：Arrhythmia, Caloric Deficit，另有 3 项

Rx

Oral GLP-1 formulation (Oralead Pharma)

机构

查看全部 280 →

Oral-B Laboratories

United States

Philips Oral Healthcare

United States

ORAL RECONSTRUCTION FOUNDATION

United States

资讯

查看全部 23219 →

去年

Aphaia Pharma Advances Oral Glucose-Based Obesity Treatment with Second Phase 2 Trial

10个月前

ICR Researchers Develop Novel Formulation Strategies to Enable Oral Delivery of VHL-based PROTACs

9个月前

临床试验

Home-based Oral Glucose Tolerance Test for Type 1 Diabetes Screening

Bioavailability Study of COQUN ORAL FORMULATION

Formulation of Compensation Based Intervention

药物

nitric oxide-based antiviral formulation

Glucose(Bss Ophthalmic Solution, Citrasate, Clinimix 2.75/5, Clinimix E 2.75/5, Dextroject, Dianeal, H.E.L.P.bicel, Hemosate Ultra, Lactate 1-2-3, Leukotrap, Naturalyte, Nauzene, Normosol-R, Nxstage Pureflow, Olimel, Periolimel, Physioneal 40, Sag-M, Sclerodex, Selectbag One)

Oral GLP-1 formulation (Oralead Pharma)

机构

Oral-B Laboratories

Philips Oral Healthcare

ORAL RECONSTRUCTION FOUNDATION

资讯

Aphaia Pharma Advances Oral Glucose-Based Obesity Treatment with Second Phase 2 Trial

ICR Researchers Develop Novel Formulation Strategies to Enable Oral Delivery of VHL-based PROTACs

MIT Develops Needle-Free Glucose Monitor Using Light-Based Technology for Diabetes Management